Finance

Relmada Stock Surges on NDV-01 Data and $160M Equity Raise

Relmada Therapeutics’ RLMD stock jumps in premarket trading after interim Phase 2 NDV-01 data for non-muscle invasive bladder cancer. 12-month interim data show a 76% overall complete response rate and 80% in the BCG-unresponsive population, with 95% CR at any time in high-risk patients. The surge is amplified by a $160 million private placement, while dilution and trial risk remain considerations.

📅 March 09, 2026
⏱️ 2 min read
Relmada Stock Surges on NDV-01 Data and $160M Equity Raise

Key Takeaways

  • RLMD trades around $6.55 in premarket, up about 47%, hitting a new 52-week high.
  • NDV-01 12-month interim data show CR 76% overall and 80% in BCG-unresponsive (with 95% at any time in high-risk patients).
  • Private placement of about $160 million raises the potential for dilution but funds late-stage development.
  • Stock shows technical strength: price well above short- and long-term SMAs with bullish momentum metrics.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Relmada Therapeutics, Inc. (RLMD) Biopharmaceutical company developing NDV-01 for bladder cancer
  • Benzinga News outlet reporting interim data

MarketMoodz Analysis

Interim NDV-01 data suggest a potentially differentiating therapy for high-risk NMIBC. A 12-month interim shows 76% overall CR, 80% in BCG-unresponsive patients, with 95% at any time in high-risk patients. If validated, the data could accelerate RESCUE Phase 3 and support a faster regulatory path, a meaningful tailwind for Relmada's pipeline. The stock move is amplified by the $160 million equity raise, which funds late-stage development but dilutes existing holders.

For investors, the key question is durability and regulatory acceptance. In biotech, standout Phase 2 signals can translate into multi-bagger rallies only if followed by confirmatory Phase 3 data and favorable regulatory decisions. The current rally hinges on a small-cap story blending strong early signals with a sizable dilutive raise; the stock could unwind if data falter or financing terms prove tougher than anticipated. Watch for RESCUE program milestones, updated NDV-01 results, and any filing updates or guidance from Relmada.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial